Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer’s disease: Where do we stand?-Reference-Cited by-同舟云学术

Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer’s disease: Where do we stand?

Published:2019-10-29 Issue:2 Volume:57 Page:99-113
ISSN:1040-8363
Container-title:Critical Reviews in Clinical Laboratory Sciences
language:en
Short-container-title:Critical Reviews in Clinical Laboratory Sciences

Author:

Veerabhadrappa Bhavana¹,Delaby Constance²³,Hirtz Christophe²,Vialaret Jérôme²,Alcolea Daniel³^ORCID,Lleó Alberto³⁴^ORCID,Fortea Juan³,Santosh Mysore Sridhar¹,Choubey Shushil⁵,Lehmann Sylvain²

Affiliation:

1. Center for Incubation Innovation Research and Consultancy (CIIRC), Jyothy Institute of Technology, Bengaluru, India;

2. INSERM U1183, Laboratoire de Biochimie-Protéomique Clinique, CHU de Montpellier, Université de Montpellier, Montpellier, France;

3. Sant Pau Memory Unit, Department of Neurology, Institut D’Investigacions Biomèdiques Sant Pau – Hospital de Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain;

4. Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain;

5. Transintegra Healthcare Pvt. Ltd, Bhubaneswar, India

Publisher

Informa UK Limited

Subject

Biochemistry, medical,Clinical Biochemistry,General Biochemistry, Genetics and Molecular Biology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10408363.2019.1678011

Reference96 articles.

1. Alzheimer's disease

2. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

3. Evaluation of CSF-tau and CSF-Aβ42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice